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Proliferation was stimulated, but interfollicular keratinocytes still underwent
normal terminal differentation. Hair follicles were abnormal, and sebaceous
differentiation was stimulated at the expense of hair differentiation. The
activation of c-Myc by a single application of 4-hydroxy-tamoxifen was as
effective as continuous treatment in stimulating proliferation and sebocyte
differentiation, and the c-Myc–induced phenotype continued to develop even
after the grafting of treated skin to an untreated recipient.
Conclusions: We propose that transient activation of c-Myc drives
keratinocytes from the stem to the transit-amplifying compartment and
thereby stimulates proliferation and differentiation along the epidermal and
sebaceous lineages. The ability, demonstrated here for the first time, to
manipulate exit from the stem cell compartment in vivo will facilitate further
investigations of the relationship between stem cells and cancer.
Background ture has defined a number of molecules that regulate exit
from the stem cell compartment [1, 2, 5]. One is theThe epidermis is maintained throughout adult life by
pluripotential stem cells whose progeny differentiate to protooncogene c-Myc [5, 6]. The activation of c-Myc
causes a progressive reduction in the growth rate of cul-form interfollicular epidermis, hair follicles, and sebaceous
glands [1–4]. Stem cell daughters that are destined to tured human keratinocytes without inducing apoptosis:
this is due to a marked stimulation of terminal differentia-undergo terminal differentiation divide a small number
of times in the basal layer before withdrawing from the tion. c-Myc acts selectively on stem cells in culture and
drives them into the transit-amplifying compartment.cell cycle; these cells are known as transit-amplifying cells.
One role of transit-amplifying cells is, as their name im- Then, after a few rounds of division, they undergo termi-
nal differentiation.plies, to increase the number of differentiated cells that
are generated by each stem cell division; in normal, un-
damaged epidermis, stem cells divide infrequently,
In clonal cultures of human keratinocytes, only differenti-whereas transit-amplifying cells are actively cycling [1, 3].
ation into interfollicular epidermis can be examined [1,A second feature of transit-amplifying cells, by analogy
6], and so it is not possible to evaluate the effects of c-Mycwith the haemopoietic system [2], may be that their differ-
on lineage commitment in vitro. In addition, stem cellsentiation potential is restricted to a particular lineage;
are actively cycling in culture, and thus the ability of Mychowever, at present little is known about lineage commit-
to recruit quiescent stem cells into the cell cycle cannotment in the epidermis.
not be evaluated [6]. Furthermore, Myc is a potent onco-
gene [7, 8] that has been reported to cause epidermal
neoplasia [9]. Constitutive expression of c-Myc via theClonal analysis of human-epidermal keratinocytes in cul-
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Figure 1
Transgene construction and expression.
(a) Diagram showing the transgene cassette.
(b) Dorsal skin of transgenic animal (founder
line 2184C.1; treated daily with OHT for 4
weeks; 3 months old when OHT treatment
was started; hair cycle not synchronized)
stained with an antibody to the murine
oestrogen receptor (HL7). As a control,
positive staining was specifically blocked by
the preincubation of the HL7 antibody with its
immunogenic peptide (HL7 1 peptide). “HF”
indicates a hair follicle; “BL” indicates the
basal layer of interfollicular epidermis; “SL”
indicates the suprabasal layers. The scale bar
represents 50 mm. (c) Western blot analysis
was performed on keratinocytes cultured from
wild-type (WT) or transgenic mice by the use
of a human c-Myc specific antibody (9E10)
or, as a loading control, anti-actin.
loricrin promoter, which targets both the basal and su- the basal layer of interfollicular epidermis and along the
entire length of the outer-root sheath of the hair follicleprabasal (differentiating) epidermal layers, results in su-
prabasal proliferation and reduced expression of terminal [11]. It thus includes both stem and transit-amplifying
cells [1, 4]. Immunostaining transgenic mouse skin con-differentiation markers in transgenic mice [10]. When an
inducible Myc transgene is selectively expressed in the firmed that the transgene was correctly expressed in the
basal layer of the epidermis and outer-root sheath of hairdifferentiating layers of mouse epidermis via the involu-
crin promoter, activation of c-Myc suppresses differentia- follicles (Figure 1b and unpublished data). Human c-Myc
was also detected by the Western blotting of extracts oftion and causes neoplastic changes; because cells express-
ing activated Myc are not permanent tissue residents, the keratinocytes cultured from transgenic but not from wild-
type mice (Figure 1c).phenotype is, however, fully reversible [9].
While the effects of c-Myc on human keratinocytes in Although c-MycER protein was constitutively expressed
in basal keratinocytes, as expected none of the founderculture are not consistent with the phenotype of trans-
genic mice expressing Myc in the epidermis, neither of lines showed any phenotype unless 4-hydroxy-tamoxifen
(OHT) was applied to activate Myc function [6, 9, 12].the transgene promoters evaluated so far [9, 10] has selec-
tively targeted the basal layer, where the stem cells reside. In addition, we saw no systemic effects of topical OHT
application to the dorsal skin of K14MycER mice, evenTherefore, to investigate the effects of c-Myc on the stem
cell compartment in vivo, we have used the keratin 14 though the K14 promoter is active in some internal epithe-
lia [13]. OHT had no effects on the skin, including thepromoter [11] to express an inducible form of Myc,
c-MycERTM, in the basal layer of transgenic mouse epider- hair cycle, of wild-type mice. As a further control, two
founder lines expressing a mutant c-Myc with a deletionmis. The phenotype we observe is consistent with a role
for Myc in promoting exit from the stem cell com- in the transactivation domain (D106–143MycER) [6] were
generated and found to exhibit no phenotypic responsepartment.
to OHT (data not shown).
Results
Generation of transgenic mice c-Myc stimulates epidermal proliferation
The dorsal skin of K14MycER and wild-type animals wasFour founder lines of transgenic mice were generated
that expressed the human c-Myc-2 cDNA fused to the treated daily with OHT for 4 weeks. The treated skin of
transgenic animals became greasy and stiff with some hairhormone binding domain (ERTM) of a mutant murine es-
trogen receptor (MycER) [12] in a keratin 14 (K14) expres- loss, whereas wild-type mouse skin was unaffected by
OHT application (data not shown). Wild-type skin wassion cassette [11] (Figure 1a). Founder line 2184C.1 had
70 copies of the transgene; 2184A had 25 copies; 2184C.2 histologically normal (Figure 2a–c), but transgenic skin
had thickened, hyperproliferative epidermis and abnor-had 2 copies; and 2184C.3 had 1 copy. ERTM lacks intrinsic
transactivation activity; it responds to the synthetic steroid mal hair follicles; normal follicle architecture was no
longer visible, and the hair fibers were often missing (Fig-4-hydroxy-tamoxifen (OHT), but not to estrogen, and so
in the absence of OHT MycER is inactive [6, 9, 12]. The ure 2d–f). Staining with the proliferation marker Ki 67
(which labels cells in late G1, S, G2, and M phases) re-K14 promoter directs transgene expression in all cells of
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Figure 2
Dorsal skin after 4 weeks of daily OHT
treatment. (a,b,c) Wild-type control mouse.
(d,e,f) Transgenic mouse (2184 C.1). Mice
were 3 months old when OHT treatment began;
the hair cycle was not synchronized. (a,d)
Hematoxylin and eosin staining. (b,e)
Immunostaining with anti–Ki 67 as a marker
for proliferating cells. (c,f) Immunostaining
with an antibody to keratin 6. Stratum corneum
staining in (c) is nonspecific. “IE” indicates
the interfollicular epidermis; “HF” indicates a
hair follicle. The scale bars represent 50 mm.
vealed an increase in the number of actively cycling cells by impaired terminal differentiation [17]. To distinguish
between these potential effects of c-Myc, we examinedin transgenic skin, the proliferative cells in interfollicular
epidermis being predominantly in the basal layer (Figure differentiation of three lineages founded by epidermal
stem cells: interfollicular epidermis, sebaceous glands,2b,e). The interfollicular epidermis was also highly posi-
tive for keratin 6, a marker for epidermal hyperprolifera- and hair follicles [1, 3, 4].
tion, which in wild-type animals is expressed exclusively
In normal interfollicular epidermis, keratin 1 is expressedin the hair follicles [14] (Figure 2c,f). Staining for markers
in all of the suprabasal layers (Figure 3c), whereas inof T lymphocytes, neutrophils, and macrophages revealed
neoplastic lesions keratin 1 expression is reduced or ab-only a small increase in immune infiltrate in OHT-treated
sent [9, 10, 17, 18]. Even though OHT-treated transgenictransgenic skin (data not shown). These results make it
epidermis was much thicker than control epidermis (Fig-unlikely that inflammation was responsible for the epider-
ure 3a,e), keratin 1 was expressed in all the suprabasalmal hyperproliferation. The phenotype was observed in
layers (Figure 3g). In addition, we noted an increasedall founder lines, although it was milder in the low than
number of keratin 1–positive cells in the basal layer ofthe high copy number lines (data not shown). Transgenic
transgenic epidermis (Figure 3c,g), which might be indica-mice aged between 7 weeks and 4 months were treated
tive of the premature initiation of terminal differentiation.with OHT; they developed the same phenotype regard-
The expression of involucrin, filaggrin, and loricrin, mark-less of age or stage of the hair growth cycle.
ers of later stages in the differentiation pathway [17, 18],
was normal (Figure 3b,f and unpublished data), and theInterfollicular epidermal differentiation is not perturbed
by c-Myc activation outermost, cornified cell layers were anucleate in both
c-Myc is known to be a potent stimulus for cells to enter transgenic and wild-type skin (Figure 2a,d and 3a,e). Su-
the cell cycle [15]. In cultures of human keratinocytes, prabasal expression of the a6b4 integrin is associated with
both stem and transit-amplifying cells are actively cycling, malignant progression in mouse skin carcinogenesis [19];
and the activation of MycER with OHT does not, there- however, a6b4 remained confined to the basal layer of
fore, recruit stem cells into the cell cycle; in addition, it OHT-treated transgenic epidermis, as in normal epider-
does not increase the number of rounds of cell division mis (Figure 3d,h). Thus, although OHT-treated trans-
that transit-amplifying cells undergo prior to terminal dif- genic interfollicular epidermis was hyperproliferative, the
ferentiation, nor does it affect the length of the cell cycle keratinocyte terminal differentiation program was essen-
[6]. In contrast to the situation in culture, in normal epider- tially normal, and the thickened epidermis comprised in-
mis stem cells are rarely in cycle, whereas transit-ampli- creased layers of differentiating cells rather than an in-
fying cells are actively cycling [16]. If the increase in creased number of basal layers.
Ki 67–positive cells in OHT-treated transgenic mouse
epidermis reflected the recruitment of quiescent stem Activation of c-Myc stimulates sebocyte differentiation
To examine differentiation of sebaceous gland cells (sebo-cells into the cycle and entry into the transit-amplifying
compartment, the consequence would be excessive pro- cytes), we stained heavily affected transgenic and wild-
type skin with Oil Red O, a histochemical dye specificduction of terminally differentiated cells. Alternatively,
if it reflected the neoplastic conversion of basal cells, the for lipid-containing cells, including sebocytes (Figure
4a,b). In wild-type skin, sebaceous glands were associatedincrease in Ki 67–positive cells might be accompanied
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Figure 3 with the upper part of each hair follicle (Figure 4a, arrow).
In transgenic mice, the number of sebocytes was greatly
increased and filled the center of the abnormal hair folli-
cle–derived structures (Figure 4b, arrows). There was no
increase in apoptotic cells in interfollicular epidermis (Fig-
ure 4c,d), and this result is consistent with other studies
showing that keratinocytes are resistant to c-Myc–induced
apoptosis [6, 9, 10]; although the lesions showing sebocyte
differentiation were strongly labeled with TUNEL, the
staining was diffuse throughout the cells rather than con-
centrated in the nucleus and may therefore be nonspecific
(Figure 4c,d). Further evidence that c-Myc promoted seb-
ocyte differentiation came from examining the specialized
sebaceous glands of the eyelid (exposed to OHT during
grooming), the meibomian glands. Similar to the seba-
ceous lesions of dorsal skin, the meibomian glands of
affected mice were enlarged (arrows in Figure 4e,f). Some
differentiated sebocytes continued to proliferate, and in
OHT-treated skin some sebocytes migrated from the hair
follicles into the overlying epidermis (data not shown);
this premalignant change is a feature of human sebaceous
carcinomas [20].
c-Myc stimulates sebocyte differentiation at the expense
of hair differentiation
The third type of differentiation we examined was the
formation of hair follicles. Hair follicles continually un-
dergo a defined cycle of growth (anagen), followed by
involution (catagen) and a resting phase (telogen) [21].
Although there was hair loss in some OHT-treated trans-
genic mice, telogen follicles were capable of initiating
anagen and the number of hair follicles in the skin was
unaltered (unpublished data). However, treated anagen
follicles had abnormal morphology, and increased num-
bers of sebocytes were observed (Figure 4h,j). Sebaceous
differentiation was also stimulated by OHT in telogen
follicles (Figure 4g,i). Severely affected transgenic skin
treated with OHT for 4 weeks and containing aberrant
follicles was stained with AE13 [22] and anti-Ha5 [23],
which recognize hair-specific keratins in the cells of the
hair matrix and cortex of normal anagen follicles. No posi-
tive staining was observed (unpublished data). It thus
appears that c-Myc stimulates sebaceous differentiation
at the expense of hair differentiation.
Transient activation of c-Myc is as effective as sustained
Expression of differentiation markers in dorsal interfollicular epidermis activation in inducing epidermal hyperproliferation
after 4 weeks of daily OHT treatment. Mice were 3 months old when and sebocyte differentiationOHT treatment began, and the hair cycle was not synchronized. (a–d)
The use of the MycER transgene allowed us to examinewild-type control mouse. (e–h) Transgenic mouse (2184 C.1). (a,e)
Hematoxylin and eosin staining. (b,f) Anti-involucrin (inv; BL, basal the effects of transient c-Myc activation. The initial half-
layer; SL, suprabasal layers), (c,g) Anti–keratin 1 (K1; arrowheads life of OHT is less than 3 days [24], and when the applied
indicate examples of K1-positive cells in the basal layer); (d,h) Antibody dose of OHT was halved, some of the K14MycER micerecognizing the a6b4 integrin. The scale bar represents 50 mm.
failed to develop a skin phenotype (data not shown).
Thus, within 3 days after the last dose of OHT, the
transgene should no longer be activated. Transgenic and
wild-type animals were treated with OHT for up to one
week and then monitored for another 6 days without
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Figure 4
(a–f) Sebaceous differentiation of
hyperproliferative lesions and (g–j) effects
of activated c-MycER on hair follicles.
(a–d,g–j) dorsal skin; (e,f) eyelid (longitudinal
sections). (a,c) Wild-type control mouse (4
weeks of daily OHT treatment), (b,d)
transgenic mouse (2184 C.1; 4 weeks of daily
OHT treatment). (a,b) Oil Red O staining with
hematoxylin and eosin counterstain; note that
subcutaneous fat stained positive with Oil
Red O in (a). (c,d) TUNEL staining (green)
with propidium iodide counterstain (red).
(a–d) Mice were 3 months old when OHT
treatment began; and the hair cycle was not
synchronized. (e–j) Hematoxylin and eosin
staining. (e) Wild-type control mouse (7 days
of OHT treatment). (f) Transgenic mouse
(2184 C.1; 7 days of OHT treatment).
Meibomian glands (MG) are outlined with
arrows. (g,h) Wild-type control animals. (i,j)
Transgenic animals (2184C.1), 7 days of OHT
treatment. Hair follicles in (g,i) telogen or (h,j)
anagen are shown. Mice in (e–g,i,j) were 2
months old at the onset of anagen, when
OHT treatment began. (h) shows anagen
follicles from a 3-month-old mouse. The scale
bars represent 100 mm.
further application of OHT (Figure 5a). The transgenic during grooming. This transfer affected the oral epi-
thelium.phenotype was not reversed but became much more se-
vere after termination of the OHT treatment (Figure 5a).
Even a single treatment with OHT caused progressive To analyze later time points and to more stringently test
whether the epidermal phenotype progressed in the ab-changes in the epidermis (Figure 5b), and in some animals
(whether receiving one or multiple doses of OHT) sponta- sence of OHT treatment, we gave wild-type and trans-
genic mice a single dose of OHT, and at intervals thereaf-neous wounds developed (see, for example, Figure 5b,
day 15). The mice could not be monitored at later time ter we removed the treated areas and grafted them onto
immunocompromised recipient mice. The grafts were re-points; they were sacrificed because they exhibited exces-
sive weight loss as a result of OHT transfer to the mouth covered 4 weeks from the date of OHT treatment. As
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Figure 5
Effects of withdrawing OHT. (a) 7-week-old
(hair follicles in telogen) transgenic
(2184C.1) and wild-type (WT) control mice
were treated daily for up to 7 days with OHT.
OHT treatment was then stopped, and animals
were analyzed after a further 6 days. (b)
transgenic (2184C.1) mice received a single
dose of OHT and were analyzed 5, 9, 14,
and 15 days later. (c) 4-month-old transgenic
(2184C.1) and wild-type (WT) control mice
were treated with a single dose of OHT. One
(transgenic) or two (WT) weeks after
treatment the animals were sacrificed, and
pieces of skin containing telogen follicles
were either processed for histology
immediately (upper panels) or were grafted
subcutaneously into nude mice and harvested
4 weeks after the inital OHT treatment
(bottom panels). “S” indicates areas of
extensive sebaceous differentiation. Dorsal
skin sections stained with hematoxylin and
eosin are shown. The scale bar represents
100 mm.
illustrated in Figure 5c, the phenotype of the transgenic one dose of OHT and sacrificed 2 weeks later, ODC
mRNA was absent, except in clusters of cells at the junc-skin was more severe than at the time of grafting and had
thickened, hyperproliferative epidermis and increased se- tion between the hair follicles and the epidermis (Figure
6e,f). These cells have previously been shown to selec-baceous differentiation, whereas grafts of OHT-treated
wild-type skin had normal histology. tively express ODC in response to phorbol ester treatment
[26]. Given that the abnormal follicle phenotype was more
highly developed in the one-dose animals examined 2Ornithine decarboxylase (ODC) is a well-documented
weeks later (Figure 6e) than in the animals treated contin-c-Myc target gene [25]. We therefore examined ODC
uously with OHT for 7 days (Figure 6c) yet that ODCexpression in transgenics treated with a single dose of
mRNA was no longer detected in those follicles, we con-OHT as a marker of whether Myc activity could persist
clude that continuous c-Myc activity was not required forin the absence of OHT (Figure 6). In wild-type epidermis
the progression of the phenotype.treated with OHT for 4 weeks, ODC mRNA was unde-
tectable in the interfollicular epidermis and upper portion
of the hair follicles, as reported previously [9], although As the histological appearance of transgenic skin treated
continuously with OHT or with a single dose was similara signal was observed at the base of the follicles (Figure
6a,b). In transgenic mice treated continuously for 7 days (Figure 5), it seemed likely that one dose of OHT was
sufficient to trigger prolonged epidermal hyperprolifera-(Figure 6c,d) or 4 weeks (unpublished data), ODC mRNA
was detected in the interfollicular epidermis and along tion. We examined this by staining for Ki 67 and by
labeling S phase cells with a 1 hr pulse of BrdU (Figurethe length of the hair follicles. In mice that were given
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Figure 6
ODC expression. In situ hybridization was
performed on the dorsal skin of (a,b) a wild-
type control mouse (the animal was 4 months
old with an asynchronous hair cycle when
OHT treatment began), (c,d) a 4-month-old
transgenic (2184A) mouse, (e,f) a 3.5-month-
old transgenic (2184A) mouse.(b,d,f) are dark
field views of (a,c,e), respectively. Arrow
heads indicate ODC mRNA in (a,b) the base
of hair follicles, (c,d) interfollicular epidermis
and abnormal follicles, and (e,f) the boundary
between hair follicle and interfollicular
epidermis. Asterisks in (e,f) indicate abnormal
follicles that do not show elevated ODC
mRNA (compare [c,d]). The scale bar
represents 100mm.
7). Five days after a single dose of OHT, Ki 67 and BrdU crease in the number of differentiated cell layers. We
propose that transient c-Myc activation recruits quiescentlabeling were stimulated; the increase in labeling was still
evident 14 days after OHT treatment (Figure 7a–i and stem cells into cycle and thereby promotes entry into the
transit-amplifying compartment, which in turn leads tounpublished data). When epidermis that had a single
OHT dose was compared with epidermis treated continu- terminal differentiation along the sebaceous and interfol-
licular epidermal lineages (Figure 8). Why sebocyte differ-ously for an equivalent period of time, the degree of
labeling was similar (see, for example, Figure 7b,g,e,j). entiation is stimulated at the expense of hair type differen-
tiation is unclear at present, but it may reflect the needThus, a single dose of OHT resulted in sustained prolifer-
ation, accounting for the progressive thickening of the for additional inducing factors, in particular Wnts, for hair-
type differentiation [27].interfollicular epidermis with time after treatment.
Discussion One characteristic of transit-amplifying cells is that they
undergo only a small number of rounds of division (vari-The aim of our experiments was to test whether activation
of c-Myc in basal keratinocytes in vivo stimulated exit ously estimated as 3–5 [1]) prior to terminal differentia-
tion. If exit from the stem cell compartment is stimulatedfrom the stem cell compartment, as observed in vitro
[6], or whether it suppressed terminal differentiation, as at the expense of self-renewal, divisions in the transit-
amplifying compartment should eventually be exhaustedobserved when Myc is selectively activated in the differ-
entiating epidermal layers [9]. A single application of and the epidermis should become thinner, with loss of
proliferation in the basal layer. However, even 30 daysOHT was as effective as repeated treatments in stimulat-
ing proliferation. However, the terminal differentiation after a single dose of OHT, the epidermis of K14MycER
mice was hyperproliferative (Figures 5 and 7). There arepathway in interfollicular epidermis was executed nor-
mally, the thickening of the epidermis reflecting an in- two possible explanations for this. One is that, as the
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Figure 7
Ki 67 and BrdU labeling of dorsal skin. (a–e)
Ki 67 staining. (f–j) BrdU labeling (green)
with a propidium iodide counterstain (red).
Green fluorescence of hair shafts is
nonspecific. (a,f) Untreated 7-week-old
transgenic mouse (hair follicles in telogen);
(b–d,g–i) 7-week-old transgenic mice in
telogen were treated with one dose of OHT
and sacrificed (b,g) 5 days, (c,h) 9 days, or
(d,i) 14 days later. (e,j) 8.5-week-old
transgenic mouse treated continuously with
OHT for 6 days; the area shown is in telogen.
The scale bar represents 50 mm.
keratin 14 promoter is expressed in both stem and transit- and transit-amplifying cells that are equivalent to those
currently available for human epidermis [1, 5, 6], it shouldamplifying cells [11], Myc activation increases the number
of rounds of division that transit cells undergo prior be possible to use the K14MycER mice to obtain an
estimate of the size of the transit-amplifying compartmentto terminal differentiation. In culture, the activation of
MycER with OHT does not increase the number of transit and to determine whether the number of rounds of divi-
sion that transit-amplifying cells undergo prior to terminalamplifying–cell divisions, nor does it affect the length of
the cell cycle [6]; however, in culture the stem cells are differentiation is fixed or responsive to environmental
modulation. A further issue is whether Myc is acting solelyactively cycling, whereas in vivo they cycle infrequently.
The second possibility is that although the production of on the keratinocyte proliferation machinery or has addi-
tional indirect effects, such as altered production oftransit-amplifying cells is stimulated, the stem compart-
ment continues to be replenished. growth factors [9], that could affect the interaction be-
tween the epidermis and the underlying mesenchymal
cells [28].By the discovery of markers of mouse epidermal stem
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Figure 8 be a consequence of c-Myc misexpression. The activation
of Myc in basal keratinocytes could also contribute to
neoplasia because any basal keratinocyte that has accumu-
lated genetic lesions resulting in resistance to cell loss
through Myc-induced terminal differentiation or apo-
ptosis would clearly have a selective growth advantage
and the potential to form a tumor.
Conclusions
The phenotype of the K14MycER mice is consistent with
a role for c-Myc in stimulating exit from the epidermal
stem cell compartment. The mice allow us to manipulate
the adult stem cell compartment in vivo and are a valuable
tool for exploring the factors that regulate lineage deci-
sions by epidermal stem cells, as well as the relationship
between stem cells and cancer.
Model of the role of c-Myc in the epidermis. c-Myc is represented as
promoting differentiation of stem cells into transit-amplifying cells
specific for the sebaceous and interfollicular epidermal lineages (red Materials and methodsarrows). The dotted red line and question mark indicate the possibility
Transgene constructionthat stem cell renewal is not inhibited.
Human c-Myc-2 cDNA, fused at its carboxy terminus to the hormone
binding domain of a mutant murine estrogen receptor (c-MycER), was
excised from pBluescript [12] as an EcoRI fragment, blunt-ended with
Klenow DNA polymerase and cloned into the blunt-ended BamHI site
The observation that the effects of MycER on epidermal of a K14 expression cassette [11] (generous gift of E. Fuchs, Howard
Hughes Medical Institute, Chicago). The K14 expression cassette (Figureproliferation and differentiation progressed even after the
1a) contains a 2100 bp AvaI fragment of the keratin 14 promoter/withdrawal of OHT is in contrast to the effects of MycER
enhancer, a rabbit b-globin 59 untranslated region (UTR) together within suprabasal keratinocytes [9] or lineage-restricted hae- an intronic sequence upstream of a BamHI site, and the K14 39 UTR
mopoietic cells [29]. When MycER is expressed in su- followed by a polyadenylation site 39 downstream of the BamHI site.
The transgene was excised from the parent plasmid as an EcoRI/HindIIIprabasal keratinocytes [9], phenotype reversal is evident
fragment, gel purified (Geneclean, Stratech Scientific), further purifiedwithin 7 days (S. Pelengaris, personal communication),
with an elutip column according to the manufacturer’s instructionswhich corresponds to the estimated turnover time of
(Schleicher and Schuell), and resuspended at a concentration of 5 mg/
mouse epidermis [30]. Whether the Myc-induced pheno- ml in sterile injection buffer (10 mM Tris-HCl, 0.1 mM EDTA [pH 7.4])
type is reversible is likely to depend on whether the for pronuclear injection.
targeted cell population consists of stem cells or differenti-
ating cells. In the latter case, upon withdrawal of OHT, Generation of transgenic mice and determination of transgene
cells with activated Myc will be lost from the tissue copy number
The transgene was injected into the male pronucleus of day-1-fertilizedthrough terminal differentiation, and the differentiation
(CBA 3 C57BL/6) F1 embryos. Founders were backcrossed to establishcompartment will be replenished by a pool of stem cells
lines of animals. Animals were screened for the presence of the transgenethat are not expressing MycER. In contrast, we are tar-
by PCR of ear DNA with primers specific for the transgene (one primer
geting the stem cells, which are permanent tissue resi- was specific for the b-globin 59 UTR, 59-TACTCTGAGTCCAAAC
dents. In this context it is striking that the increased CGGGC-39; the other specific for c-myc-2, 59-AGCCTGGTAGGA
GGCCAGCTTCTCTGA-39). To determine transgene copy number, weproliferation in the basal layer is not dependent on contin-
performed Southern blotting on genomic DNA isolated from tail snipsuous activation of the transgene. One potential mecha-
and digested overnight with HindII and SacI. Blots were probed with a
nism by which transient activation of Myc could result in radiolabeled 1.2 kb human c-myc-2 cDNA probe and with a probe to
sustained effects on the behavior of keratinocytes would the single copy gene interleukin 2 receptor a (as described previously)
[18].be Myc-induced histone acetylation and chromatin re-
modeling [31], but this remains to be investigated.
Experimental treatments of mice
The c-MycER transgene was activated in transgenic mice by topicalWhile our data suggest that c-Myc promotes epidermal
application of 4-hydroxy-tamoxifen (OHT; Sigma) to a shaved area ofdifferentiation, they do not exclude a proneoplastic role dorsal skin (1 mg dissolved in 0.2 ml ethanol; dose, 1 mg per mouse
for Myc in the epidermis. In normal epidermis c-Myc per day). Wild-type littermates were used as controls. No sex-specific
effects of OHT were observed. In some experiments, mice received anexpression is confined to the basal layer, whereas su-
intraperitoneal injection of BrdU (0.1 mg/g body weight) 1 hr prior toprabasal, differentiating keratinocytes express members
sacrifice. In some experiments, pieces of dorsal skin (approximately 1of the Mad family [32–35], which are c-Myc antagonists. cm2) from OHT-treated wild-type and transgenic mice were grafted under
The neoplastic phenotype induced by the expression of the back skin of Balb/c nude mice, essentially as described previously
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